ABOUT
_edited.png)
GTBVP At A
Glance.
The Global TB Vaccine Partnership brings together funders, product developers, and policymakers working jointly to address barriers and create opportunities to help accelerate the development of safe and effective TB vaccines.
Launched in 2011 by TBVI, Aeras, the European Commission, and the European Investment Bank, and with early support from the Bill and Melinda Gates Foundation, the initiative today has 13 members representing European, South African, and US governments, EU institutions, private foundations, product development partnerships, and global health organisations. The full membership can be reviewed here.
Priority areas for action by the GTBVP are to address the need for guidelines, policies, and resources to enhance TB-vaccine related research and product development, and to coordinate and align the efforts of the members of GTBVP in support of the global TB vaccine development pipeline.
The GTBVP also supported the development of two TB vaccine initiatives in collaboration with our partner organisations: the TB Vaccine Development Pathway and a review of the current status of TB vaccine research and development.
Our Goals.
-
Identify and address gaps in R&D that are potential barriers to successfully develop new effective, affordable, and accessible vaccines
-
Stimulate discussions among key stakeholders in TB vaccine R&D, and facilitate collaboration and coordination in research, policy, and funding actions
-
Make GTBVP information and resources available to the broader TB vaccine R&D community
